Xilio Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Xilio Therapeutics, Inc. (XLO) reported Increase Decrease In Operating Lease Liability of -$278.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2025-05-08
- Xilio Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-03-31 was -$278.00K.
- Xilio Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2024-12-31 was -$273.00K.
- Xilio Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2024-09-30 was -$267.00K.
- Xilio Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2024-06-30 was -$263.00K.
- Xilio Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$1.05M.
- Xilio Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$918.00K.
- Xilio Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$801.00K.
- Xilio Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2021 was -$564.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-03-31 | -$278.00K 10-Q · filed 2025-05-08 | -$551.00K derived: sum of 2 quarters · filed 2025-05-08 | -$818.00K derived: sum of 3 quarters · filed 2025-05-08 | -$1.08M derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | -$273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$540.00K derived: sum of 2 quarters · filed 2025-03-11 | -$803.00K derived: sum of 3 quarters · filed 2025-03-11 | -$1.05M 10-K · filed 2025-03-11 |
| 2024-09-30 | -$267.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$530.00K derived: sum of 2 quarters · filed 2024-11-07 | -$774.00K 10-Q · filed 2024-11-07 | -$1.01M derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-06-30 | -$263.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$507.00K 10-Q · filed 2024-08-08 | -$746.00K derived: sum of 3 quarters · filed 2025-05-08 | -$981.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-03-31 | -$244.00K 10-Q · filed 2025-05-08 | -$483.00K derived: sum of 2 quarters · filed 2025-05-08 | -$718.00K derived: sum of 3 quarters · filed 2025-05-08 | -$949.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$239.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$474.00K derived: sum of 2 quarters · filed 2025-03-11 | -$705.00K derived: sum of 3 quarters · filed 2025-03-11 | -$918.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | -$235.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$466.00K derived: sum of 2 quarters · filed 2024-11-07 | -$679.00K 10-Q · filed 2024-11-07 | -$889.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$231.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$444.00K 10-Q · filed 2024-08-08 | -$654.00K derived: sum of 3 quarters · filed 2024-08-08 | -$859.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$213.00K 10-Q · filed 2024-05-14 | -$423.00K derived: sum of 2 quarters · filed 2024-05-14 | -$628.00K derived: sum of 3 quarters · filed 2024-05-14 | -$829.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$210.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$415.00K derived: sum of 2 quarters · filed 2024-04-01 | -$616.00K derived: sum of 3 quarters · filed 2024-04-01 | -$801.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$205.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$406.00K derived: sum of 2 quarters · filed 2023-11-09 | -$591.00K 10-Q · filed 2023-11-09 | -$772.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$201.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$386.00K 10-Q · filed 2023-08-14 | -$567.00K derived: sum of 3 quarters · filed 2023-08-14 | -$745.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$185.00K 10-Q · filed 2023-05-09 | -$366.00K derived: sum of 2 quarters · filed 2023-05-09 | -$544.00K derived: sum of 3 quarters · filed 2023-05-09 | -$719.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$181.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$359.00K derived: sum of 2 quarters · filed 2023-03-02 | -$534.00K derived: sum of 3 quarters · filed 2023-03-02 | -$564.00K 10-K · filed 2023-03-02 |
| 2021-09-30 | -$178.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$353.00K derived: sum of 2 quarters · filed 2022-11-09 | -$383.00K 10-Q · filed 2022-11-09 | -$669.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$175.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$205.00K 10-Q · filed 2022-08-09 | -$491.00K derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | -$30.00K 10-Q · filed 2022-05-12 | -$316.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$286.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$415.00K 10-K · filed 2022-03-01 | ||
| 2020-09-30 | -$129.00K 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |